Tun daga farkon kulle-kulle na Maris 2020 don ƙwayar cuta ta SARS-CoV-2, an yi watsi da batun rigakafi na halitta (wanda ake kira rigakafin kamuwa da cuta bayan kamuwa da cuta). Da zarar allurar rigakafin ta zama ruwan dare gama gari, abin da ya fara da kusan shiru a farkon ya juya ya zama baƙar fata na batun.
[Bayanin Edita: Tun daga lokacin an haɓaka wannan labarin zuwa wani yanki na ci gaba da karatun 81.]
Har yanzu, babu wata tattaunawa a fili, mai yiwuwa don inganta rigakafin rigakafi na duniya da kuma takaddun da ake buƙata na irin wannan rigakafin a matsayin yanayin shiga cikin rayuwar jama'a har ma da kasuwannin ayyuka. Har ila yau, ilimin yana wanzu. Akwai karatu da yawa. Mawallafansu sun cancanci yabo, karramawa, da kuma jin muryoyinsu.
Waɗannan karatun suna nuna abin da aka sani kuma an riga an san shi: rigakafi na halitta don ƙwayar cuta irin ta SARS tana da ƙarfi, mai dorewa, kuma mai fa'ida sosai har ma a yanayin maye gurbi, gabaɗaya fiye da alluran rigakafi. A haƙiƙa, babbar gudummawar kimiyya ta ƙarni na 20 ita ce faɗaɗawa da ƙara fayyace wannan ƙa'idar da aka sani tun zamanin d ¯ a. Kowane ƙwararren mai yiwuwa ya san wannan tun kafin muhawarar da ake yi a yanzu. Ƙoƙarin yin kamanceceniya ce ta kimiyya ta mafi girman tsari, musamman saboda ci gaba da yin watsi da batun yana shafar haƙƙoƙin biliyoyin mutane.
Mutanen da suka kamu da kwayar cutar kuma suka murmure sun cancanci girmamawa. Sanin cewa rigakafi na halitta - wanda ya shafi yanzu ga watakila rabin yawan jama'ar Amurka da biliyoyin duniya - yana da tasiri wajen ba da kariya ya kamata ya yi tasiri sosai kan umarnin rigakafin.
Mutanen da ake lalata rayuwarsu da ’yancinsu da share suna buƙatar samun damar yin amfani da littattafan kimiyya kamar yadda ya shafi wannan ƙwayar cuta. Su aika hanyar haɗi zuwa wannan shafin nesa da nesa. Masana kimiyya ba su yi shiru ba; kawai dai ba su sami kulawar jama'a da ya kamata ba. Shirye-shiryen wannan jeri ya taimaka ta hanyar haɗin da aka bayar Paul Iliya Alexander da Rational Ground nasa takardar yaudara akan rigakafi na halitta, wanda kuma ya haɗa da hanyoyin haɗi zuwa shahararrun labaran kan batun.
1. shekara guda ya ci gaba da kare lafiyar salula da ban dariya na COVID-19 convalescents, na Jie Zhang, Hao Lin, Beiwei Ye, Min Zhao, Jianbo Zhan, et al. Cutar cututtuka na Clinical, Oktoba 5, 2021. "SARS-CoV-2-specific IgG antibodies, da kuma NAb na iya ci gaba a tsakanin fiye da 95% COVID-19 convalescents daga watanni 6 zuwa watanni 12 bayan kamuwa da cuta. IgM antibody da SARS-CoV-19 a 71m bayan kamuwa da cuta musamman, da kashi na convalescents tare da tabbatacce SARS-CoV-26-takamaiman amsawar T-cell (aƙalla daya daga cikin SARS-CoV-19 antigen S2, S12, M da N protein) sun kasance 2/2 (1%) da 2% (71%). Bugu da ƙari, duka matakan ƙwaƙwalwar ƙwayar cuta da ƙwayoyin T-cell na masu karɓa suna da alaƙa da tsananin cutar su. "
2. Kwatanta garkuwar halitta ta SARS-CoV-2 zuwa rigakafi da ke haifar da rigakafi: sake kamuwa da kamuwa da cuta, na Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon. MedRxiv, Agusta 25, 2021. "Binciken mu ya nuna cewa SARS-CoV-2-naïve alluran rigakafi yana da 13.06-ninka ƙara hadarin kamuwa da cuta tare da bambance-bambancen Delta idan aka kwatanta da wadanda suka kamu da a baya, lokacin da na farko taron (kamuwa da cuta ko alurar riga kafi) ya faru a watan Janairu da Fabrairu na 2021. The ƙara hadarin da kuma na halitta iya nuna alama. kariya mai dorewa kuma mai ƙarfi daga kamuwa da cuta, cututtukan alamomi da asibiti saboda bambance-bambancen Delta na SARS-CoV-2, idan aka kwatanta da BNT162b2 rigakafi-kashi biyu-biyu.
3. Zubar da Cutar SARS-CoV-2 Duk da Alurar riga kafi, na Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Gunnar E. Jeppson, David H. O'Connor, Thomas C. Friedrich, Katarina M. Grande, MedRxiv, Agusta 24, 2021. "Sassarar SARS-CoV-2 Delta na iya haifar da babban juzu'i na rigakafi wanda ke ƙunshe da ƙwayoyin cuta mai saurin kamuwa da cuta. Binciken da aka yi ya nuna cewa mutanen da aka yi wa alurar riga kafi za su iya yaɗa Delta Mun kwatanta bayanan RT-PCR daga samfuran swab 699 da aka tattara a cikin Wisconsin 29 ga Yuni zuwa 31 ga Yuli 2021 kuma an gwada su ta hanyar gwajin kwangila guda ɗaya. A wannan lokacin, kiyasin bambance-bambancen Delta ya karu daga 36% zuwa sama da 81%.
4. Wajabcin rigakafin COVID-19 a cikin mutanen da suka kamu da cutar a baya, da Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, Paul Terpeluk, Steven M. Gordon, MedRxiv, Yuni 5, 2021.
5. Babban karatu na lalata titer na antibody bayan maganin BNT162b2 mRNA ko kamuwa da SARS-CoV-2, na Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen. MedRxiv, Agusta 22, 2021. "Wannan binciken ya nuna mutanen da suka karɓi allurar Pfizer-BioNTech mRNA suna da nau'ikan matakan rigakafi daban-daban idan aka kwatanta da marasa lafiya waɗanda suka kamu da kwayar cutar ta SARS-CoV-2, tare da matakan farko na farko amma raguwa mai saurin fa'ida a rukunin farko."
6. Sa hannu na Amsar Kariya mai Wa'azi ga SARS-CoV-2 mRNA Alurar riga kafi da kamuwa da cuta, ta Ellie Ivanova, Joseph Devlin, et al. Cell, Mayu 2021. "Yayin da duka kamuwa da cuta da allurar rigakafi suka haifar da innate mai ƙarfi da martani na rigakafi, bincikenmu ya nuna bambance-bambance masu mahimmanci tsakanin nau'ikan ƙalubalen rigakafi guda biyu.
7. Cutar SARS-CoV-2 tana haifar da ƙwayoyin jini na kasusuwan kasusuwa na dogon lokaci a cikin mutane, ta Jackson S. Turner, Wooseob Kim, Elizaveta Kalaidina, Charles W. Goss, Adriana M. Rauseo, Aaron J. Schmitz, Lena Hansen, Alem Haile, Michael K. Klebert, Iskra Pusic, Jane A. O'Halloran, Rachel M. Presti, Ali H. Ellebedy. Yanayin, Mayu 24, 2021. "Wannan binciken ya nemi sanin ko kamuwa da cuta tare da SARS-CoV-2 ya haifar da antigen-takamaiman BMPCs na tsawon lokaci a cikin mutane. kamuwa da cuta ta SARS-CoV-2 yana haifar da amsawar kwayar halitta ta T-cell B, wanda farkon fashewar ƙwayoyin plasma na jini ya haifar da guguwar ƙwayoyin rigakafi waɗanda ke raguwa cikin sauri.
8. Bincike na dogon lokaci yana nuna ƙwaƙwalwar ajiya mai ƙarfi da fa'ida bayan kamuwa da cuta ta SARS-CoV-2 tare da ci gaba da amsawar rigakafi da ƙwayoyin B da T., ta Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, Julie Czartoski, Lilin Lai, Grace Mantus, Carson Norwood, Lindsay E. Nyhoff, Venkata Viswanadh Edara, et al. MedRxiv, Afrilu 27, 2021. "Ƙarshen cutar ta COVID-19 na buƙatar rigakafi mai tsawo ga SARS-CoV-2. Mun kimanta marasa lafiya 254 COVID-19 a tsawon lokaci daga farkon kamuwa da cuta kuma har tsawon watanni takwas bayan haka kuma mun sami babban martani mai fa'ida na tushen rigakafi. na> kwanaki 2 suna ba da shawarar haɓakar ƙwayoyin plasma masu tsayi da yawa Bugu da ƙari, an sami ci gaba da amsawar IgG + ƙwaƙwalwar ajiyar ƙwayar cuta, wanda ke ba da sakamako mai kyau ga saurin amsawar rigakafin ƙwayar cuta.
9. Haɗuwa da Cutar Cutar Cutar Cutar Cutar Coronavirus-2 tsakanin ma'aikatan da suka kamu da cutar a baya ko kuma waɗanda aka yi musu allurar., ta N Kojima, A Roshani, M Brobeck, A Baca, JD Klausner. MedRxiv, Yuli 8, 2021. "Cutar cutar ta SARS-CoV-2 da ta gabata da allurar rigakafin SARS-CoV-2 an danganta su da raguwar haɗarin kamuwa da cuta ko sake kamuwa da cuta tare da SARS-CoV-2 a cikin ma'aikatan da aka bincika akai-akai. Ba wani bambanci ba ne a cikin kamuwa da kamuwa da cuta tsakanin mutanen da aka yi wa alurar riga kafi da daidaikun mutanen da ke da kamuwa da cuta ta baya. iri-iri."
10. Siffar tantanin halitta guda ɗaya na repertoires cell T da B suna bin rigakafin SARS-CoV-2 mRNA, na Suhas Sureshchandra, Sloan A. Lewis, Brianna Doratt, Allen Jankeel, Izabela Ibraim, Ilhem Messaoudi. BioRxiv, Yuli 15, 2021. "Abin sha'awa, clonally fadada CD8 T Kwayoyin da aka lura a cikin kowane maganin alurar riga kafi, kamar yadda aka lura biyo bayan halitta kamuwa da cuta. TCR gene amfani, duk da haka, ya kasance m, yana nuna bambancin repertoires da MHC polymorphism a cikin yawan mutane. Halittar kamuwa da cuta ya haifar da fadada daga cikin manyan CD8 T cell clones, mai yiwuwa ya haifar da fa'ida daga manyan CD4 T cell clones. An gabatar da kwayar cutar da ba a gani a cikin rigakafin mRNA ba.
11. Kwayoyin T da ke haifar da rigakafin mRNA suna amsa iri ɗaya ga bambance-bambancen SARS-CoV-2 na damuwa amma sun bambanta cikin tsawon rai da kaddarorin gida dangane da matsayin kamuwa da cuta ta farko., Jason Neidleman, Xiaoyu Luo, Matthew McGregor, Guorui Xie, Victoria Murray, Warner C. Greene, Sulggi A. Lee, Nadia R. Roan. BioRxiv, Yuli 29, 2021. "A cikin kamuwa da cuta-wahala mutane, kashi na biyu ya inganta yawa da kuma canza phenotypic Properties na SARS-CoV-2-takamaiman T Kwayoyin, yayin da a convalescents kashi na biyu ya canza ba. Dorewa na dogon lokaci da iyawar gida ga sassan numfashi ciki har da nasopharynx Wadannan sakamakon suna ba da tabbacin cewa ƙwayoyin T da aka haifar da alurar rigakafi suna ba da amsa da ƙarfi ga bambance-bambancen ƙwayar cuta, sun tabbatar da cewa masu jin daɗin rayuwa ba za su buƙaci kashi na biyu na rigakafin ba, kuma suna ba da shawarar cewa masu maganin alurar riga kafi na iya samun ƙarin nasopharynx-homing-kamar kamuwa da cutar SARS-2.
12. Ƙwaƙwalwar rigakafi zuwa SARS-CoV-2 an kimanta har zuwa watanni 8 bayan kamuwa da cuta, Jennifer M. Dan, Jose Mateus, Yu Kato, Kathryn M. Hastie, et al., Kimiyya, Janairu 6, 2021. "Fahimtar ƙwaƙwalwar ajiyar rigakafi zuwa SARS-CoV-2 yana da mahimmanci don inganta bincike da alluran rigakafi, kuma don tantance yiwuwar makomar cutar ta COVID-19. Mun bincika sassan da yawa na ƙwaƙwalwar ƙwayar cuta ta SARS-CoV-2 a cikin ƙwaƙwalwar ajiyar ƙwayar cuta ta SARS-CoV254. Abubuwan COVID-188, gami da samfuran 19 a cikin watanni 43 bayan kamuwa da cuta, IgG zuwa furotin na Spike ya kasance mai ƙarfi fiye da watanni 6+ B cell, CD6+ T cell, da CD6+ T cell memory zuwa SARS-CoV-1 a cikin hadedde hanya, mun lura cewa kowane bangare na SARS-CoV-2 ƙwaƙwalwar ajiyar rigakafi yana nuna bambancin motsin rai. "
13. Dagewar kawar da ƙwayoyin rigakafi shekara guda bayan kamuwa da cutar SARS-CoV-2, na Anu Haveri, Nina Ekström, Anna Solastie, Camilla Virta, Pamela Österlund, Elina Isosaari, Hanna Nohynek, Arto A. Palmu, Merit Melin. MedRxiv, Yuli 16, 2021. "Mun kimanta dagewar kwayoyin rigakafin cutar sankarau sakamakon kamuwa da cuta na SARS-CoV-2 na daji watanni shida da goma sha biyu bayan ganewar asali a cikin mutane 367 wanda 13% daga cikinsu suna da mummunar cutar da ke buƙatar asibiti. (NAB)."
14. Ƙididdiga haɗarin sake kamuwa da SARS-CoV-2 akan lokaci, na Eamon O Murchu, Paula Byrne, Paul G. Carty, et al. Rev Med Virol. 2021. "Reinfection wani abu ne wanda ba a sani ba (cikakkiyar ƙimar 0% -1.1%), ba tare da wani binciken da ke ba da rahoto game da karuwa a cikin hadarin reinfection a tsawon lokaci ba. Ɗaya daga cikin binciken ya kiyasta yawan haɗarin yawan yawan jama'a na reinfection bisa ga dukkanin jerin kwayoyin halitta a cikin ƙananan marasa lafiya; hadarin da aka kiyasta ya kasance ƙananan (0.1-95%) [0.08]. Rage rigakafi har zuwa watanni 0.11 sakamakon kamuwa da cuta ta farko.
15. SARS-CoV-2 antibody-positivity yana karewa daga sake haifuwa na aƙalla watanni bakwai tare da inganci 95%, na Laith J. Abu-Raddad, Hiam Chemaitelly, Peter Coyle, Joel A. Malek. The Lancet, Yuli 27, 2021. "Sake kamuwa da cuta ba kasafai ba ne a cikin matasa da al'ummar Qatar. Cutar ta dabi'a ta bayyana tana ba da kariya mai ƙarfi daga sake kamuwa da cuta tare da inganci ~ 95% na akalla watanni bakwai."
16. Kariyar dabi'a daga COVID-19 yana rage haɗarin sake kamuwa da cuta: bincike daga ƙungiyar mahalarta binciken sero, by Bijaya Kumar Mishra, Debdutta Bhattacharya, Jaya Singh Kshatri, Sanghamitra Pati. MedRxiv, Yuli 19, 2021. "Wadannan binciken yana ƙarfafa ƙwaƙƙwaran gaskiyar cewa ci gaban antibody bayan kamuwa da cuta na halitta ba wai kawai yana kare kariya daga sake kamuwa da kwayar cutar ba har ma da kariya daga ci gaba zuwa mummunar cutar COVID-19."
17. Kariyar kamuwa da cutar SARS-CoV-2 da ta gabata yayi kama da na kariyar rigakafin BNT162b2: Kwarewar wata uku a cikin ƙasa daga Isra'ila., by Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert, et al .. MedRxiv, Afrilu 24, 2021. "Hakazali, da overall kimanta matakin kariya daga kafin SARS-CoV-2 kamuwa da cuta: 94. 8 · 94]); asibiti 4 · 95% (CI: [1 · 94, 1 · 91]); da kuma rashin lafiya mai tsanani 9 · 95% (CI: [7 · 96, 4 · 92]).
18. Ƙwaƙwalwar rigakafi a cikin Marasa lafiya COVID-19 mai sauƙi da masu ba da gudummawa da ba a bayyana ba suna Bayyana Amsoshin Takardun Kwayoyin T Bayan Cutar SARS-CoV-2, ta Asgar Ansari, Rakesh Arya, Shilpa Sachan, Someshwar Nath Jha, Anurag Kalia, Anupam Lall, Alessandro Sette, et al. gaban Immunol. Maris 11, 2021. "Amfani da HLA class II annabta peptide megapools, mun gano SARS-CoV-2 giciye-reactive CD4+ T Kwayoyin a kusa da 66% na unexposed mutane. Bugu da ƙari, mun sami detectable rigakafi ƙwaƙwalwar ajiya a cikin m COVID-19 marasa lafiya watanni da dama bayan murmurewa a cikin muhimman makamai na m adaptive rigakafi rigakafi; CD4+ tare da T-Centre T. Ƙwaƙwalwar ƙwaƙwalwar ajiyar rigakafi a cikin marasa lafiya na COVID-8 galibi ana niyya ne ga Spike glycoprotein na SARS-CoV-19.
19. Gwajin kawar da kwayar cutar ta kai tsaye a cikin marasa lafiya da abubuwan da aka yi wa allurar rigakafin 19A, 20B, 20I/501Y.V1 da 20H/501Y.V2 na SARS-CoV-2, ta Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, et al, MedRxiv, Mayu 11, 2021. "Ba a sami wani gagarumin bambanci tsakanin 20B da 19A ware ga HCWs tare da m COVID-19 da kuma m marasa lafiya. Duk da haka, an sami raguwa mai mahimmanci a cikin iyawar neutralization don kwatantawa tare da 20I. Marasa lafiya da HCW watanni 501 bayan kamuwa da cuta Game da 1H/19Y.V6, duk yawan jama'a sun sami raguwa mai yawa wajen kawar da titin antibody idan aka kwatanta da keɓancewar 20A.
20. Amsar rigakafin ƙwayar cuta ta musamman mai aiki a cikin kamuwa da cutar SARS-CoV-2 mai asymptomatic, by Nina Le Bert, Hannah E. Clapham, Anthony T. Tan, Wan Ni Chia, et al, Journal of Gwajin Medicine, Maris 1, 2021. "Don haka, asymptomatic SARS-CoV-2-cutar mutane ba a halin da rauni antiviral rigakafi; akasin haka, sun mount a sosai aiki virus-specific martani na kwayar cutar."
21. SARS-CoV-2-takamaiman ƙwaƙwalwar ƙwayar ƙwayar ƙwayar cuta ta T tana dawwama a cikin marasa lafiya na COVID-19 na tsawon watanni 10 tare da nasarar haɓakar ƙwayoyin ƙwayoyin ƙwaƙwalwar ƙwayar cuta kamar T.. Alamar, adadin ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar ƙwayar cuta ta tabbatar da ci gaban TSCM 30 DPSO ). yuwuwar ingantaccen shirye-shiryen rigakafin a matsayin ma'auni don sarrafa COVID-2021."
22. Juyin Juyin Halitta bayan SARS-CoV-2 mRNA Alurar riga kafi, ta Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew, Zijun Wang, et al, BioRxiv, et al, BioRxiv, Yuli 29, 2021. ƙaruwa mai yawa a cikin ayyukan kawar da jini na plasma amma ba fa'ida mai inganci akan bambance-bambancen da aka samu ta hanyar yin allurar rigakafin mutane ba." Sabon salo Ya karanta: "Wadannan sakamakon sun ba da shawarar cewa haɓaka mutanen da ke da allurar rigakafin mRNA a halin yanzu zai haɓaka ayyukan kawar da jini amma maiyuwa ba zai samar da ƙwayoyin rigakafi masu faɗi daidai da waɗanda aka samu ta hanyar yin allurar rigakafin mutane ba."
23. Daban-daban na kashi na biyu na rigakafin SARS-CoV-2 mRNA akan rigakafin T cell a cikin butulci da COVID-19 da aka murmure., ta Carmen Camara, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados. Et al., BioRxiv, Maris 27, 2021. "Yayin da aka nuna tsarin rigakafi na kashi biyu tare da maganin BNT162b2 don samar da tasiri na 95% a cikin mutane masu butulci, sakamakon kashi na biyu na maganin alurar riga kafi a cikin mutanen da suka warke a baya daga SARS-CoV-2 na halitta an yi tambaya. Rashin rigakafi a cikin mutanen da suka kamu da cutar a baya yayin cikakken rigakafin BNT2b162, sakamakonmu ya nuna cewa kashi na biyu yana haɓaka rigakafi na raha da na salula a cikin mutane butulci. SARS-CoV-2."
24. COVID-19 rigakafi na halitta: Brief na Kimiyya. Hukumar Lafiya Ta Duniya. Mayu 10, 2021. "Bayanan kimiyya da aka samu sun nuna cewa a yawancin mutane martanin rigakafi sun kasance masu ƙarfi da kariya daga kamuwa da cuta na akalla watanni 6-8 bayan kamuwa da cuta (mafi tsayin bin diddigin hujjojin kimiyya mai ƙarfi a halin yanzu kusan watanni 8). rigakafi na salula wanda kamuwa da cuta ta dabi'a ke haifarwa shima yana kai hari ga sauran sunadaran ƙwayoyin cuta, waɗanda galibi ana kiyaye su a cikin bambance-bambancen fiye da furotin mai karu."
25. SARS-CoV-2 hadarin sake kamuwa da cuta a Austria, ta Stefan Pilz, Ali Chakeri, John Pa Ioannidis, et al. Eur J Clin Invest. Afrilu 2021. "Mun rubuta 40 tentative sake kamuwa da cuta a cikin 14 840 COVID-19 tsira daga farkon kalaman (0.27%) da 253 581 cututtuka a cikin 8 885 640 mutane na sauran jama'a (2.85%) fassara cikin wani rashin daidaito rabo (95% 0.09). An lura da ƙarancin sake kamuwa da cuta na SARS-CoV-0.07 a cikin Ostiriya Kariya daga SARS-CoV-0.13 bayan kamuwa da cuta ta dabi'a yana kama da mafi girman ƙididdiga akan ingancin rigakafin.
26. Amsar anti-spike antibody ga cututtukan SARS-CoV-2 na halitta a cikin yawan jama'a, ta Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al, MedRxiv, Yuli 5, 2021. "Mun kiyasta matakan rigakafin rigakafi da ke da alaƙa da kariya daga sake kamuwa da cuta mai yiwuwa na wuce shekaru 1.5-2 a matsakaici, tare da matakan da ke da alaƙa da kariya daga kamuwa da cuta mai tsanani na shekaru da yawa. Waɗannan ƙididdiga na iya ba da sanarwar tsara dabarun haɓaka rigakafin rigakafi."
27. Yawan kamuwa da cuta na SARS-CoV-2 na antibody-tabbatacce idan aka kwatanta da ma'aikatan kula da lafiya marasa kyau a Ingila: babban, cibiyar da yawa, binciken ƙungiyar masu zuwa (SIREN)), ta Victoria Jane Hall, FFPH, Sarah Foulkes, MSc, Andre Charlett, PhD, Ana Atti, MSc, et al. The Lancet, Afrilu 29, 2021. "A baya tarihi na SARS-CoV-2 kamuwa da cuta yana hade da wani 84% m hadarin kamuwa da cuta, tare da tsaka-tsaki sakamako lura watanni 7 bayan primary kamuwa da cuta. Wannan lokaci lokaci ne mafi m m sakamako saboda seroconversions ba a hada da.
28. Martanin SARS-CoV-2 Na Halitta na Antibody Ya Dage na Aƙalla watanni 12 a cikin Nazarin Ƙasashen Duniya Daga Tsibirin Faroe, by Maria Skaalum Petersen, Cecilie Bo Hansen, Marnar Fríheim Kristiansen, et al, Bude Forum Cututtuka masu Yaduwa, Volume 8, fitowar 8, Agusta 2021. "Ko da yake ba a san aikin kariya na kwayoyin cutar ba a halin yanzu, sakamakonmu ya nuna cewa SARS-CoV-2 rigakafi ya ci gaba da kasancewa a kalla watanni 12 bayan bayyanar cututtuka na COVID-19. Ana iya kiyaye mutane daga kamuwa da cuta. Sakamakonmu yana wakiltar rigakafi na SARS-CoV-2 a cikin ƙungiyoyin ƙasa baki ɗaya a cikin yanayin da ba a gano shi ba, kuma mun yi imanin cewa sakamakonmu yana ƙara fahimtar rigakafi na halitta da dorewar rigakafin rigakafin SARS-CoV-2.
29. Ƙungiyoyin Alurar riga kafi da kamuwa da cuta ta farko tare da ingantacciyar sakamakon gwajin PCR na SARS-CoV-2 a cikin Fasinjojin Jirgin da suka isa Qatar, na Roberto Bertollini, MD, MPH1; Hiam Chemaili, MSc2; Hadi M. Yassine. JAMA Research Letter, Yuni 9, 2021. "Daga cikin mutane 9180 ba tare da rikodin allurar rigakafi ba amma tare da rikodin kamuwa da cuta a baya aƙalla kwanaki 90 kafin gwajin PCR (rukuni 3), 7694 za a iya daidaitawa da mutanen da ba su da rikodin alurar riga kafi ko kamuwa da cuta kafin kamuwa da cuta (rukuni 2), wanda PCR positivity ya kasance 1.01% 95% -0.80%) da 1.26% (3.81% CI, 95% -3.39%), bi da bi. alurar riga kafi ko kafin kamuwa da cuta."
30. Duban dogon lokaci na martanin rigakafin mutum na tsawon watanni 14 bayan kamuwa da cutar SARS-CoV-2, by Puya Dehgani-Mobaraki, Asiya Kamber Zaidi, Nidhi Yadav, Alessandro Floridi, Emanuela Floridi. Clinical Immunology, Satumba 2021. "A Kammalawa, Sakamakon bincikenmu ya yi daidai da binciken da aka yi kwanan nan wanda ke ba da rahoton dagewar rigakafin cutar da ke nuna cewa haifar da rigakafin SARS-CoV-2 ta hanyar kamuwa da cuta, na iya yin tasiri sosai game da sake kamuwa da cuta (> 90%) kuma yana iya dagewa sama da watanni shida. Bincikenmu ya biyo bayan marasa lafiya har zuwa watanni 14 yana nuna kasancewar anti-S-RBD IgG a cikin kashi 96.8% na abubuwan COVID-19 da aka dawo dasu. ”
Labarai a cikin shahararrun kafofin watsa labarai
Me yasa bai kamata a buƙaci allurar COVID-19 ga Duk Amurkawa ba, ta Marty Makary, Labaran Amurka, Agusta 21, 2021
Samun SARS-CoV-2 sau ɗaya yana ba da rigakafi mafi girma fiye da maganin alurar riga kafi - amma rigakafin yana da mahimmanci., ta Meredith Wadson, Kimiyya, Agusta 26, 2021
Kamuwa da cuta na halitta vs alurar riga kafi: Wanne ya ba da ƙarin kariya? Daga David Rosenberg, Labaran Isra'ila na ƙasa, Yuli 13, 2021.
Wadanda suka tsira daga mura har yanzu suna samun kariya bayan shekaru 90, ta Ed Yong, National Geographic, Agusta 17, 2008.
Soke Dokokin Alurar rigakafi: Buɗe Wasika zuwa Ƙungiyoyin Kiwon Lafiya, Asibitoci, Asibitoci, da Sauran Kayan Aikin Kiwon Lafiya, Ƙungiyar Likitocin Amirka da Likitoci, Agusta 31, 2021.
Alurar riga kafi na Jami'a ta yi umarni da keta da'a na likitanci, Daga Aaron Kheriaty da Gerard V. Bradley, Wall Street Journal, Yuni 14, 2021.
Kariya ga Coronavirus na iya shekarun da suka gabata, Sabbin Bayanan Bayanai, ta Apoorva Mandavilli, New York Times, Nuwamba 17, 2020.
COVID-19 yana haifar da dawwamammen kariya na rigakafin mutum, Tamari Bhandara, Makarantar Magunguna ta Jami'ar Washington, Mayu 24, 2021.
Hukumar Lafiya ta Duniya ta yi galaba a kan allurar rigakafin cutar da kuma rashin rigakafi, na Jeffrey Tucker, Cibiyar Brownstone, Agusta 29, 2021.
Me yasa CDC ke Gane rigakafi na Halitta don Cutar Kaji amma Ba Covid? Daga Paul Elias Alexander, Cibiyar Brownstone, Satumba 17, 2021.
Rand Paul da Xavier Becerra Square Kashe Kan Kariya na Halitta, tare da Mummunan Sakamako, ta Cibiyar Brownstone, Oktoba 2, 2021.
Lockdowns, Wajibai, da Kariya na Halitta: Kulldorff vs. Offit, ta Cibiyar Brownstone, Oktoba 6, 2021.
Asibitoci yakamata suyi hayar, ba wuta ba, ma'aikatan jinya masu rigakafi na halitta, na Martin Kulldorff, Oktoba 1, 2021.
Bakon Rashin Kula da Lafiyar Halitta, ta Jayanta Bhattacharya, Cibiyar Brownstone, Yuli 28, 2021.
-
Labarai daga Cibiyar Brownstone, ƙungiyar sa-kai da aka kafa a watan Mayu na 2021 don tallafawa al'umma da ke rage rawar tashin hankali a rayuwar jama'a.
Duba dukkan posts
